This author has not written his bio yet.
But we are proud to say that Andrew Humphreys contributed 3897 entries already.
The U.S. drug regulator declined to approve Sesen Bio Inc.’s lead therapy candidate for a type of bladder cancer, the company said on Aug. 13, sending its shares down more than 80 percent.
A study in Science shed new light on the global epidemic obesity by evaluating nearly 650,000 exomes from the United Kingdom, United States and Mexico and identifying those with strong implications for body mass or obesity.
Ashfield Health, a global healthcare marketing and communications network and part of UDG Healthcare, announced and welcomed William Martino as Growth Director, North America. In this new role, Martino is leading business development for Ashfield Health and Mind+Matter, an Ashfield Health agency.
Drugmakers Pfizer, BioNTech and Moderna are expected to reap billions of dollars from Covid-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come, analysts and healthcare investors say.
After discussions with the U.S. Food and Drug Administration, Paris-based Ipsen withdrew the company’s New Drug Application (NDA) for palovarotene.
Indian vaccine maker Bharat Biotech’s nasal Covid-19 vaccine candidate received regulatory approval for mid-stage to late-stage trials, the government’s ministry of science and technology said in a statement on Aug. 13.
The cities of San Francisco and New Orleans on Aug. 12 ordered patrons to show proof of Covid-19 vaccinations to enter restaurants, gyms and other venues, joining New York in a severe step designed to contain the fast-spreading Delta variant.
Covid-19 probably can be eradicated globally, just like polio, according to research just published in BMJ Global Health. That assumes, however, that a high rate of vaccination occurs globally and that there is a quick response to emerging variants.
PharmaLive talked to Milan Kalawadia – Senior Vice President, Head of US Commercial Operations for Dr. Reddy’s Laboratories – about facing challenges from the COVID-19 pandemic; obstacles going forward for generic drug companies; customer relationships; and other industry-related topics.
Combining medical information (MI) and pharmacovigilance (PV) has been shown to drive an array of positive outcomes, including accelerating adverse event intake, improving healthcare professional and patient communications, intelligently connecting enterprise systems and importantly, driving better patient safety. New innovations in connected technologies are finally making it possible to combine elements of these functions in a thoughtful way. However, the change from legacy processes and mindset will be significant and driving employee adoption to see the benefit of these investments will require careful change management. IQVIA’s Annette Williams and Libbie McKenzie explore considerations for leaders looking to combine aspects of their MI and PV functions and how they can effectively roll out this shift to maximize the benefits to their organizations along with patients, providers, and other key stakeholders.
